{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:25:57Z","timestamp":1761585957886,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010230","name":"Qinghai University Young and Middle-aged Research Fund","doi-asserted-by":"publisher","award":["2016-QYY-14"],"award-info":[{"award-number":["2016-QYY-14"]}],"id":[{"id":"10.13039\/501100010230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010230","name":"Qinghai University Affiliated Hospital 2017 Academic Innovation Research Fund Project","doi-asserted-by":"publisher","award":["FYXC-2017-14"],"award-info":[{"award-number":["FYXC-2017-14"]}],"id":[{"id":"10.13039\/501100010230","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.intimp.2020.106380","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:46:05Z","timestamp":1585892765000},"page":"106380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Analysis of serum rheumatoid factors in patients with rheumatoid arthritis in Han, Tibetan and Hui nationalities in Qinghai"],"prefix":"10.1016","volume":"83","author":[{"given":"Xia","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sen","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TaiJi","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2020.106380_b0005","first-page":"175","article-title":"One year in review 2018: pathogenesis of rheumatoid arthritis","volume":"36","author":"Calabresi","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/ard.2005.044354","article-title":"EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"66","author":"Combe","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.berh.2004.08.008","article-title":"How to predict prognosis in early rheumatoid arthritis","volume":"19","author":"Morel","year":"2005","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0020","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/rheumatology\/32.suppl_3.9","article-title":"The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease","volume":"32","author":"van Leeuwen","year":"1993","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0025","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1600-0609.1983.tb01547.x","article-title":"Influence of plasma proteins on erythrocyte morphology and sedimentation","volume":"31","author":"Talstad","year":"1983","journal-title":"Scand. J. Haematol."},{"key":"10.1016\/j.intimp.2020.106380_b0030","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/ard.2006.068247","article-title":"High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study","volume":"67","author":"Syversen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.autrev.2008.07.031","article-title":"A new strategy for the early diagnosis of rheumatoid arthritis: a combined approach","volume":"8","author":"Tedesco","year":"2009","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2020.106380_b0040","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/ard.2006.051391","article-title":"Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review","volume":"65","author":"Avouac","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0045","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s10067-009-1206-z","article-title":"Very recent onset arthritis: the value of initial rheumatologist evaluation and anti-cyclic citrullinated peptide antibodies in the diagnosis of rheumatoid arthritis","volume":"28","author":"Rojas-Serrano","year":"2009","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/art.21518","article-title":"Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-\u03baB-dependent signal transduction pathway","volume":"54","author":"Mullan","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106380_b0055","first-page":"657","article-title":"Plasma ferritin determination as a diagnostic tool","volume":"145","author":"Finch","year":"1986","journal-title":"West. J. Med."},{"key":"10.1016\/j.intimp.2020.106380_b0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0308-2261(21)00338-6","article-title":"Ferritin in human tissues and serum","volume":"11","author":"Worwood","year":"1982","journal-title":"Clin. Hematol."},{"key":"10.1016\/j.intimp.2020.106380_b0065","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0002-9343(99)80015-1","article-title":"Extremely elevated serum ferritin levels in a university hospital: associated diseases and clinical significance","volume":"98","author":"Lee","year":"1995","journal-title":"Am. J. Med."},{"key":"10.1016\/j.intimp.2020.106380_b0070","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/08916934.2013.873413","article-title":"Therapeutic targets for rheumatoid arthritis: progress and promises","volume":"47","author":"Alghasham","year":"2014","journal-title":"Autoimmunity."},{"key":"10.1016\/j.intimp.2020.106380_b0075","first-page":"551","article-title":"One year in review: the pathogenesis of rheumatoid arthritis","volume":"33","author":"Picerno","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0080","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","article-title":"Rheumatoid arthritis","volume":"388","author":"Smolen","year":"2016","journal-title":"The Lancet"},{"issue":"2010","key":"10.1016\/j.intimp.2020.106380_b0085","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106380_b0100","doi-asserted-by":"crossref","first-page":"211","DOI":"10.5371\/hp.2017.29.4.211","article-title":"Diagnosis and treatment of inflammatory joint disease","volume":"29","author":"Kim","year":"2017","journal-title":"Hip. Pelvis."},{"key":"10.1016\/j.intimp.2020.106380_b0105","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","article-title":"New therapies for treatment of rheumatoid arthritis","volume":"370","author":"Smolen","year":"2007","journal-title":"The Lancet"},{"key":"10.1016\/j.intimp.2020.106380_b0110","doi-asserted-by":"crossref","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","article-title":"Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis","volume":"51","author":"Choy","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2020.106380_b0115","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mehy.2018.10.007","article-title":"Rheumatoid arthritis revisited","volume":"122","author":"Suominen","year":"2019","journal-title":"Med. Hypotheses."},{"key":"10.1016\/j.intimp.2020.106380_b0120","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/sj.gene.6363677","article-title":"IL-6 promoter polymorphisms in rheumatoid arthritis","volume":"1","author":"Pascual","year":"2000","journal-title":"Genes Immun."},{"key":"10.1016\/j.intimp.2020.106380_b0125","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0889-857X(21)00933-9","article-title":"Rheumatoid factor","volume":"13","author":"Chen","year":"1987","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"10.1016\/j.intimp.2020.106380_b0130","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fmed.2018.00185","article-title":"The utility and limitations of CRP, ESR and DAS28-CRP in appraising disease activity in rheumatoid arthritis","volume":"5","author":"Orr","year":"2018","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.intimp.2020.106380_b0135","doi-asserted-by":"crossref","unstructured":"R.M. Nakamura, Progress in the use of biochemical and biological markers for evaluation of rheumatoid arthritis, J. Clin. Lab. Ana. 14 (2000) 305\u2013313. https:\/\/doi.10.1002\/1098-2825(20001212)14:6<305:: aid-jcla10>3.0.co;2-p.","DOI":"10.1002\/1098-2825(20001212)14:6<305::AID-JCLA10>3.0.CO;2-P"},{"key":"10.1016\/j.intimp.2020.106380_b0140","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/ard.60.10.924","article-title":"Predictors of radiographic joint damage in patients with early rheumatoid arthritis","volume":"60","author":"Jansen","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0145","doi-asserted-by":"crossref","first-page":"R796","DOI":"10.1186\/ar1740","article-title":"Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score","volume":"7","author":"Aletaha","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2020.106380_b0150","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5152\/eurjrheumatol.2014.024","article-title":"The clinical utility of anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis","volume":"1","author":"\u015eim\u015fek","year":"2014","journal-title":"Eur. J. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/jcla.21638","article-title":"Anticyclic citrullinated peptide antibody and rheumatoid factor in south Tunisian patients with rheumatoid arthritis: association with disease activity and severity","volume":"28","author":"Hamad","year":"2014","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.intimp.2020.106380_b0160","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/ard.2004.033571","article-title":"Longitudinal analysis of citrullinated protein\/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression","volume":"64","author":"Ronnelid","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0165","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1136\/ard.2009.122739","article-title":"Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis","volume":"69","author":"Miriovsky","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0170","doi-asserted-by":"crossref","first-page":"17917","DOI":"10.1038\/s41598-018-36335-x","article-title":"Extracellular vesicles are associated with the systemic inflammation of patients with seropositive rheumatoid arthritis","volume":"8","author":"Burbano","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.intimp.2020.106380_b0175","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.2119\/molmed.2011.00186","article-title":"Serum amyloid A directly accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice","volume":"17","author":"Dong","year":"2011","journal-title":"Mol. Med."},{"key":"10.1016\/j.intimp.2020.106380_b0180","first-page":"14","article-title":"Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C-reactive protein","volume":"24","author":"Kumon","year":"1997","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0185","first-page":"535","article-title":"Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts","volume":"78","author":"Migita","year":"1998","journal-title":"Lab. Invest."},{"key":"10.1016\/j.intimp.2020.106380_b0190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cccn.2005.04.006","article-title":"Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA\/CRP ratio","volume":"360","author":"Kokubun","year":"2005","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.intimp.2020.106380_b0195","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1136\/ard.2007.073825","article-title":"Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors","volume":"67","author":"Jorgensen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0200","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","article-title":"Role of cytokines in rheumatoid arthritis","volume":"14","author":"Feldmann","year":"1996","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2020.106380_b0205","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2006.058529","article-title":"Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis","volume":"65","author":"Koenders","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2020.106380_b0210","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3109\/s10165-009-0217-6","article-title":"Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis","volume":"19","author":"Kageyama","year":"2009","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.intimp.2020.106380_b0215","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1002\/art.24672","article-title":"Genetic susceptibility to rheumatoid arthritis: an emerging picture","volume":"61","author":"Barton","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106380_b0220","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1002\/art.11224","article-title":"Can we accurately predict the development of rheumatoid arthritis in the preclinical phase?","volume":"48","author":"Majka","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106380_b0225","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","author":"Wellcome Trust Case Control Consortium","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2020.106380_b0230","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1002\/art.21419","article-title":"Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles","volume":"52","author":"Irigoyen","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2020.106380_b0235","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/rheumatology\/kel052","article-title":"Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis","volume":"46","author":"Kaltenh\u00e4user","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2020.106380_b0240","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/rheumatology\/kem343","article-title":"Auto-antibodies, HLA and PTPN22: susceptibility markers for rheumatoid arthritis","volume":"47","author":"Orozco","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2020.106380_b0245","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1002\/art.21739","article-title":"The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis","volume":"54","author":"der Helm-van Mil","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.intimp.2020.106380_b0250","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00125817-200203000-00002","article-title":"A comprehensive review of genetic association studies","volume":"4","author":"Hirschhorn","year":"2002","journal-title":"Genet. Med."},{"key":"10.1016\/j.intimp.2020.106380_b0255","first-page":"676","article-title":"Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis","volume":"59","author":"Mulcahy","year":"1996","journal-title":"Am. J. Hum. Genet."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920300667?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576920300667?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:19:03Z","timestamp":1761585543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576920300667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":49,"alternative-id":["S1567576920300667"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106380","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analysis of serum rheumatoid factors in patients with rheumatoid arthritis in Han, Tibetan and Hui nationalities in Qinghai","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2020.106380","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106380"}}